Skip to main content
Veterinary Medicines

Avishield IB H120, lyophilisate for oculonasal suspension/use in drinking water, for chickens

Authorised
  • Avian infectious bronchitis virus, type Massachusetts, strain H120, Live

Product identification

Medicine name:
Avishield IB H120, lyophilisate for oculonasal suspension/use in drinking water, for chickens
Avishield IB H120, lyofilisaat voor oculonasale suspensie/gebruik in drinkwater, voor kippen
Avishield IB H120, lyophilisat pour suspension oculonasale/administration dans l'eau de boisson, pour poulets
Avishield IB H120, Lyophilisat zur Herstellung einer Suspension zur oculonasalen Anwendung / zum Eingeben über das Trinkwasser, für Hühner
Active substance:
  • Avian infectious bronchitis virus, type Massachusetts, strain H120, Live
Target species:
  • Chicken
Route of administration:
  • Oculonasal use
  • In drinking water use

Product details

Active substance and strength:
  • Avian infectious bronchitis virus, type Massachusetts, strain H120, Live
    3.50
    unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate for oculonasal suspension/use in drinking water
Withdrawal period by route of administration:
  • Oculonasal use
    • Chicken
      • Meat and offal
        0
        day
  • In drinking water use
    • Chicken
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD07
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • Carton box with 10 vials of 1000 doses of vaccine. Colourless glass vials (type I), which are closed with bromobutyl rubber stoppers and sealed with aluminium caps.
  • Carton box with 10 vials of 2500 doses of vaccine. Colourless glass vials (type I), which are closed with bromobutyl rubber stoppers and sealed with aluminium caps.
  • Carton box with 10 vials of 5000 doses of vaccine. Colourless glass vials (type I), which are closed with bromobutyl rubber stoppers and sealed with aluminium caps.

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Genera d.d.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Genera d.d.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V526000
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0292/001
Concerned member states:
  • Austria
  • Belgium
  • Croatia
  • Czechia
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 7/06/2023
French (PDF)
Published on: 7/06/2023
German (PDF)
Published on: 7/06/2023

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 7/06/2023
French (PDF)
Published on: 7/06/2023
German (PDF)
Published on: 7/06/2023

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 7/06/2023
French (PDF)
Published on: 7/06/2023
German (PDF)
Published on: 7/06/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."